64 related articles for article (PubMed ID: 9212920)
1. Ex vivo bone marrow purging with oligonucleotides.
Bergan RC
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):251-5. PubMed ID: 9212920
[No Abstract] [Full Text] [Related]
2. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging.
Bergan R; Hakim F; Schwartz GN; Kyle E; Cepada R; Szabo JM; Fowler D; Gress R; Neckers L
Blood; 1996 Jul; 88(2):731-41. PubMed ID: 8695822
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
4. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.
Clark RE
Leukemia; 2000 Mar; 14(3):347-55. PubMed ID: 10720125
[TBL] [Abstract][Full Text] [Related]
5. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
de Fabritiis P; Amadori S; Calabretta B; Mandelli F
Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
[TBL] [Abstract][Full Text] [Related]
6. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
7. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
[TBL] [Abstract][Full Text] [Related]
8. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
9. Ribozyme mediated therapy for chronic myelogenous leukemia.
Leopold LH; Shore SK; Newkirk T; Mangan K; Reddy EP
Prog Clin Biol Res; 1994; 389():175-82. PubMed ID: 7700900
[No Abstract] [Full Text] [Related]
10. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation.
Yuan T; Zhou YQ; Herst CV; Reading C; Ellersen D; Etkin M; Khouri I; Kantarjian H; Talpaz M; Deisseroth A
Prog Clin Biol Res; 1992; 377():227-30. PubMed ID: 1438419
[No Abstract] [Full Text] [Related]
11. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
[TBL] [Abstract][Full Text] [Related]
12. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
Dilloo D; Hanenberg H; Lion T; Burdach S
Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
[TBL] [Abstract][Full Text] [Related]
13. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
de Fabritiis P; Calabretta B
Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
[No Abstract] [Full Text] [Related]
15. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
[TBL] [Abstract][Full Text] [Related]
16. Polymerase chain reaction: a method for monitoring tumor cell purge by long-term culture in BCR/ABL positive acute lymphoblastic leukemia.
Fabrega S; Laporte JP; Giarratana MC; Douay L; Fouillard L; Da WM; Perrot C; Barbu V; Gorin NC
Bone Marrow Transplant; 1993 Feb; 11(2):169-73. PubMed ID: 8435666
[TBL] [Abstract][Full Text] [Related]
17. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses.
Spiller DG; Giles RV; Broughton CM; Grzybowski J; Ruddell CJ; Tidd DM; Clark RE
Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):281-93. PubMed ID: 9743466
[TBL] [Abstract][Full Text] [Related]
18. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of retroviral transduction in chronic myelogenous leukemia.
Claxton D; Suh SP; Filaccio M; Ellerson D; Gaozza E; Andersson B; Brenner M; Reading C; Feinberg A; Moen R
Hum Gene Ther; 1991; 2(4):317-21. PubMed ID: 1665348
[TBL] [Abstract][Full Text] [Related]
20. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]